Adial Pharma holders boost authorized shares to 500M
Adial’s shareholders approved expanded equity plans and a fivefold increase in authorized shares, while adjourning votes on four Nasdaq-related proposals to October 1, 2026.
Rhea-AI Filing Summary
Adial Pharmaceuticals, Inc. (ADIL) reported results from its 2026 Annual Meeting of Stockholders held on September 17, 2026. Stockholders approved Amendment No. 8 to the 2017 Equity Incentive Plan, a new 2026 Equity Incentive Plan, and a 2026 Employee Stock Purchase Plan, expanding the company’s ability to grant equity-based compensation. They also approved an amendment to the certificate of incorporation increasing authorized common shares from 100,000,000 to 500,000,000, and approved the potential issuance of up to 552,940 shares upon exercise of Series F warrants to comply with Nasdaq Listing Rule 5635(d). An adjournment proposal was approved, and the meeting was partially adjourned with respect to four other proposals tied to Nasdaq approvals; those proposals will be voted when the meeting reconvenes on October 1, 2026.
Positive
- None.
Negative
- None.
Filing Explained
Stockholders elected Cary J. Claiborne and Robertson H. Gilliland as Class II directors through the 2029 annual meeting, but the company disclosed that both are expected to resign shortly after all proposals are approved. Because proposals 3–6 remain pending until the meeting reconvenes on
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Shares outstanding entitled to vote: 2,625,890 shares
Shares present or represented: 1,278,677 shares (48.7%)
Authorized common shares before and after amendment: 100,000,000 to 500,000,000 shares
+5 more
8 metrics
Shares outstanding entitled to vote
2,625,890 shares
Common stock outstanding and entitled to vote as of the record date for the 2026 Annual Meeting
Shares present or represented
1,278,677 shares (48.7%)
Shares present or represented by proxy at the 2026 Annual Meeting, constituting a quorum
Authorized common shares before and after amendment
100,000,000 to 500,000,000 shares
Increase in authorized common stock approved in Proposal 7
Series F warrant shares approved
552,940 shares
Maximum aggregate common shares issuable upon exercise of Series F warrants under the 2025 Warrant Exercise Proposal
Votes for Proposal 7 (authorized share increase)
1,239,968 votes for
Stockholder approval of amendment to increase authorized common stock
Votes for adjournment proposal
1,246,908 votes for
Approval to adjourn the 2026 Annual Meeting if necessary or appropriate
Director election votes for Cary J. Claiborne
831,079 votes for
Election of Class II director to serve until the 2029 Annual Meeting
Director election votes for Robertson H. Gilliland
826,834 votes for
Election of Class II director to serve until the 2029 Annual Meeting
Key Terms
Equity Incentive Plan, Employee Stock Purchase Plan, Nasdaq Listing Rule 5635(d), Adjournment Proposal, +1 more
5 terms
Equity Incentive Plan financial
"approved the 2017 Plan Amendment, the 2026 Plan and the 2026 ESPP"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Employee Stock Purchase Plan financial
"approved the Adial Pharmaceuticals, Inc. 2026 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Nasdaq Listing Rule 5635(d) regulatory
"for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance"
Nasdaq Listing Rule 5635(d) is a stock-exchange rule that determines when a company must get shareholder approval before issuing new shares tied to conversions or exercises of existing convertible securities, options or warrants. It matters to investors because it controls potential dilution of their holdings and changes in voting power—think of it like a rule that decides whether a previously agreed‑upon coupon can be redeemed without asking the group again.
Adjournment Proposal regulatory
"approved the proposal to adjourn the 2026 Annual Meeting to a later date"
An adjournment proposal is a formal request made at a shareholder or board meeting to pause the meeting and reconvene at a later date or time. It matters to investors because it postpones votes and decisions, giving parties extra time to gather information, solicit support, negotiate alternatives or introduce new options — like hitting pause on a group decision to wait for more facts, which can alter outcomes and market reactions.
Initial Listing Application regulatory
"Nasdaq’s conditional approval of the Initial Listing Application that the Company submitted"
An initial listing application is a company’s formal request to a stock exchange to have its shares offered publicly for the first time. Investors care because the application starts a review of the company’s finances, governance and disclosures—like a store deciding whether to carry a new product—so approval affects when shares become tradable, how much scrutiny the company faces, and the potential liquidity and price discovery for investors.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What key actions did ADIL stockholders approve at the 2026 Annual Meeting?
Stockholders approved Amendment No. 8 to the 2017 Equity Incentive Plan, a new 2026 Equity Incentive Plan, a 2026 Employee Stock Purchase Plan, an increase in authorized common shares to 500,000,000, the 2025 Warrant Exercise Proposal, and an adjournment proposal.
What is the ADIL 2025 Warrant Exercise Proposal that was approved?
Stockholders approved, for Nasdaq Listing Rule 5635(d) purposes, the issuance of up to an aggregate of 552,940 shares of common stock upon exercise of Series F common stock purchase warrants issued in a private placement that closed on November 28, 2025.
Why was the ADIL 2026 Annual Meeting partially adjourned and when will it reconvene?
The meeting was adjourned solely for Proposals 3, 4, 5 and 6 to allow time to obtain necessary Nasdaq approvals. It is scheduled to reconvene on October 1, 2026, at 8:30 a.m. Eastern Time at the company’s Charlottesville, Virginia offices.
Were ADIL’s director nominees elected at the 2026 Annual Meeting?
Yes. Cary J. Claiborne and Robertson H. Gilliland were elected as Class II directors, with 831,079 and 826,834 votes for, respectively. Each is expected to resign as a director shortly after all proposals in the definitive proxy statement are approved.
Which independent auditor did ADIL stockholders ratify for 2026?
Stockholders ratified CBIZ CPAs P.C. (f/k/a Marcum, LLP) as Adial’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 1,256,114 votes for, 20,974 against, and 1,589 abstentions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
